Self-Study 2026: Cancer Cachexia Management (phase 2 in pipeline)

Type: Individual•Format: On-demand

Cancer cachexia is a complex metabolic syndrome characterized by systemic inflammation and abnormal energy metabolism in approximately half of patients with advanced cancer diagnoses. Evidence has shown patients with cancer cachexia have worse cancer outcomes complicated by delays and dose reductions in treatment. Previous recommendations for management have shown mixed and limited benefit in improving cancer cachexia.

This module will explore recent updates to guidelines based on emerging literature as well as a review of phase 2 agents in the pipeline. These advances are promising for improving management and outcomes in this poorly defined and studied population.

Cancer Cachexia Management (phase 2 in pipeline)

Author: Emma Sullivan, PharmD, BCOP, CPP - Clinical Pharmacist Specialist, Malignant Hematology

Learning Objectives

  1. Review current pharmacologic and nonpharmacologic therapies in the management of cancer cachexia
  2. Explain the role of biomarkers and novel targets in the pathophysiology and treatment of cancer cachexia
  3. Assess evidence supporting currently available therapies for cachexia in cancer patients
  4. Evaluate the safety and effectiveness of cancer cachexia drugs in the pipeline

Get it here

Application Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.